Also BD1 under the Radar,
Last two trading days,
Two Great Ann's:
Today:
• Australian Patent No. 2015218188 granted to BARD1 by IP Australia
• Provides patent protection for hTERT in Australia until 2035
Melbourne, Australia, 15 March 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or Company) announces that it has been granted Australian patent number 2015218188 entitled ‘Method of Detecting Cancer’. Australian patent 2015218188 covers the use of the Company’s hTERT antibody to resolve inconclusive cytology and detect malignant cells.
Friday:
• BARD1 gains Class II IVD device registration for hTERT from South Korea’s Ministry of Food and Drug Safety
• BARD1’s exclusive Korean distributor Mirax places first hTERT product order Melbourne, Australia, 12 March 2021:
BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that it has gained Class II In-Vitro Diagnostic (IVD) medical device registration from South Korea’s Ministry of Food and Drug Safety (MFDS) for the Company’s hTERT test, which is used as an adjunct to urine cytology testing.
Both not marked price sensitive for some reason.
Prostate cancer test results on the way,
Their other tests have been near 100% accurate:
Griffith University releases additional data on BARD1’s SubB2M technology showing 100% specificity
and over 95% sensitivity for detection of all stages of Breast Cancer
• BARD1 aims to develop and commercialise SubB2M-based blood tests for breast cancer to enable earlier detection, inform treatment decisions and improve women’s health outcomes
Melbourne, Australia, 15 February 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that Griffith University’s Institute for Glycomics has now released data showing that SubB2M can be used to detect all stages of breast cancer with 100% specificity and over 95% sensitivity from a blood sample.
Griffith University releases data on BARD1’s SubB2M technology showing 100% specificity and sensitivity
for detection of all stages of ovarian cancer
Paper presenting this data at the Australia New Zealand Gynaecological Oncology Group (ANZGOG) Conference 2021
Melbourne, Australia, 11 February 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that Griffith University’s Institute of Glycomics has released data showing that SubB2M can be used to detect all stages of ovarian cancer with 100% specificity and 100% sensitivity.
Would already be worth Billions if it were a US Company,
Which will likely be looking at BD1 for a potential Take Over.
Prostate Cancer Test Results due shortly,
Which would then nearly cover the Entire Population....
